Glioblastoma is one of the most lethal cancers in central nervous system, and some
individual cells that cannot be isolated for surgical resection and also show treatment …

Glioblastoma multiforme (GBM) is the most common type of primary and malignant tumor
occurring in the adult central nervous system. Temozolomide (TMZ) has been considered to …

Glioma remains one of the most aggressive and lethal cancers in central nervous system.
Temozolomide (TMZ) is the most commonly used chemotherapeutic agent in gliomas …

Malignant glioma is a highly aggressive brain tumor with a poor prognosis. Chemotherapy
has been observed to prolong overall survival rate and temozolomide (TMZ), a promising …

Glioblastoma (GBM) is the most aggressive type of glioma. Temozolomide (TMZ) is currently
the drug of choice used for post-operative chemotherapy of GBM. However, the presence of …

Abstract O 6-methylguanine DNA methyltransferase (MGMT) can remove DNA alkylation
adducts, thereby repairing damaged DNA and contributing to the drug resistance of gliomas …

Background The use of temozolomide (TMZ) has improved the prognosis for glioblastoma
multiforme patients. However, TMZ resistance may be one of the main reasons why …

It was reported that MGMTlow gliomas may still be resistant to TMZ, while the mechanisms
remain poorly understood. In this study, we demonstrated that rho-associated kinase 2 …

Background Temozolomide (TMZ) resistance remains the main therapy challenge in
patients with glioblastoma multiforme (GBM). TTK Protein Kinase (TTK) contributes to the …

Temozolomide (TMZ) is a novel cytotoxic alkylating agent for chemotherapy of malignant
gliomas. However, intrinsic or acquired resistance to TMZ often defines poor efficacy of …